Tvardi Therapeutics (NASDAQ:TVRD) Downgraded to Sell Rating by Wall Street Zen

Key Points

• Tvardi Therapeutics was downgraded from a "hold" to a **"sell" rating** by Wall Street Zen, alongside several other recent downgrades from analysts like Piper Sandler and Raymond James.
• The company's stock has seen significant volatility, with a **52-week low of $5.65** and a high of **$43.65**, currently trading at approximately **$6.58**.
• Tvardi reported a disappointing quarterly earnings result, with an **EPS loss of $1.00** that fell short of analysts' expectations, leading to a negative net margin of **678.79%**.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday.

Other equities research analysts also recently issued research reports about the stock. Piper Sandler downgraded shares of Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, October 13th. Raymond James Financial downgraded shares of Tvardi Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Tuesday. BTIG Research cut their target price on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a "buy" rating for the company in a research report on Monday, October 13th. Cantor Fitzgerald downgraded shares of Tvardi Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, October 13th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Tvardi Therapeutics in a research report on Tuesday. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $55.50.

Tvardi Therapeutics Price Performance

Shares of NASDAQ:TVRD opened at $6.58 on Friday. Tvardi Therapeutics has a 52 week low of $5.65 and a 52 week high of $43.65. The company has a 50 day moving average price of $30.22.

Tvardi Therapeutics (NASDAQ:TVRD - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Slate Path Capital LP acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter worth $16,427,000. 683 Capital Management LLC acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter worth $4,107,000. Geode Capital Management LLC acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter worth $2,617,000. Marshall Wace LLP acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter worth $583,000. Finally, Bank of America Corp DE acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter worth $399,000. Institutional investors and hedge funds own 44.66% of the company's stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.